| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 5 | 2021 | 189 | 0.690 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.600 |
Why?
|
| Cholestasis | 1 | 2018 | 154 | 0.510 |
Why?
|
| Disasters | 2 | 2022 | 103 | 0.360 |
Why?
|
| Hypertension, Portal | 2 | 2020 | 78 | 0.300 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2007 | 8 | 0.280 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2007 | 12 | 0.270 |
Why?
|
| Carcinoma | 2 | 2021 | 290 | 0.260 |
Why?
|
| Conjunctiva | 1 | 2007 | 197 | 0.240 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 398 | 0.230 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2016 | 73 | 0.220 |
Why?
|
| Nocardia Infections | 1 | 2024 | 14 | 0.220 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 55 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2024 | 51 | 0.210 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 150 | 0.200 |
Why?
|
| Disaster Medicine | 1 | 2022 | 8 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1526 | 0.200 |
Why?
|
| Insulins | 1 | 2022 | 17 | 0.200 |
Why?
|
| Homozygote | 1 | 2024 | 547 | 0.190 |
Why?
|
| Disaster Planning | 1 | 2022 | 63 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 668 | 0.190 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 8 | 0.190 |
Why?
|
| Child | 17 | 2024 | 24559 | 0.180 |
Why?
|
| Rhabdomyosarcoma | 1 | 2024 | 191 | 0.180 |
Why?
|
| Granuloma, Pyogenic | 1 | 2020 | 5 | 0.180 |
Why?
|
| Thyroid Gland | 1 | 2021 | 104 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1248 | 0.180 |
Why?
|
| Cough | 2 | 2020 | 94 | 0.170 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 71 | 0.170 |
Why?
|
| Military Personnel | 1 | 2022 | 210 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 306 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 862 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1659 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2024 | 878 | 0.160 |
Why?
|
| Orchiectomy | 1 | 2019 | 51 | 0.160 |
Why?
|
| Liver Diseases | 2 | 2024 | 368 | 0.160 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 714 | 0.150 |
Why?
|
| Trachea | 1 | 2020 | 203 | 0.150 |
Why?
|
| Osteosarcoma | 2 | 2018 | 255 | 0.150 |
Why?
|
| Adolescent | 15 | 2021 | 19441 | 0.150 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 2 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 91 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2019 | 138 | 0.150 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.150 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.150 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 49 | 0.150 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.150 |
Why?
|
| Portal Vein | 1 | 2018 | 93 | 0.150 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 25 | 0.150 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2018 | 37 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 132 | 0.150 |
Why?
|
| Pruritus | 1 | 2018 | 41 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 372 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 101 | 0.140 |
Why?
|
| beta Carotene | 1 | 2018 | 41 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2020 | 249 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 152 | 0.140 |
Why?
|
| Biliary Atresia | 1 | 2020 | 190 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2022 | 641 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 241 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 31 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 38 | 0.140 |
Why?
|
| Male | 19 | 2024 | 61776 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 115 | 0.130 |
Why?
|
| Humans | 29 | 2024 | 125667 | 0.130 |
Why?
|
| Wolman Disease | 1 | 2016 | 7 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2018 | 121 | 0.130 |
Why?
|
| Polyps | 1 | 2017 | 44 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 117 | 0.130 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 11 | 0.130 |
Why?
|
| Galectin 3 | 1 | 2016 | 36 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 258 | 0.130 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 8 | 0.120 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 16 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 25 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 19 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 31 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2015 | 13 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Thyroid Nodule | 1 | 2015 | 19 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2015 | 23 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1901 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 48 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2015 | 57 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 933 | 0.120 |
Why?
|
| Liver | 2 | 2016 | 1749 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2016 | 101 | 0.120 |
Why?
|
| Stomach | 1 | 2017 | 270 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 106 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1039 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5195 | 0.110 |
Why?
|
| Mutation | 2 | 2020 | 5893 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 152 | 0.110 |
Why?
|
| Pollen | 1 | 2014 | 46 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 359 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 512 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 427 | 0.110 |
Why?
|
| Fungi | 1 | 2014 | 69 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1318 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1201 | 0.110 |
Why?
|
| Anus Diseases | 1 | 2013 | 12 | 0.110 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 327 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2021 | 213 | 0.100 |
Why?
|
| Allergens | 1 | 2014 | 252 | 0.100 |
Why?
|
| Child, Preschool | 8 | 2020 | 14106 | 0.100 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 383 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 548 | 0.090 |
Why?
|
| Female | 16 | 2024 | 66998 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2013 | 279 | 0.080 |
Why?
|
| Infant | 6 | 2024 | 12572 | 0.080 |
Why?
|
| Thyroidectomy | 2 | 2021 | 100 | 0.080 |
Why?
|
| Young Adult | 6 | 2020 | 9093 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1705 | 0.080 |
Why?
|
| Coccidioidomycosis | 1 | 2008 | 12 | 0.070 |
Why?
|
| Biopsy | 3 | 2017 | 1241 | 0.070 |
Why?
|
| Actomyosin | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 37 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 418 | 0.070 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2006 | 8 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1204 | 0.070 |
Why?
|
| Placenta | 2 | 2008 | 509 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 66 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2007 | 55 | 0.070 |
Why?
|
| Chorioamnionitis | 1 | 2006 | 42 | 0.070 |
Why?
|
| Stillbirth | 1 | 2006 | 79 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2007 | 128 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 1 | 2007 | 109 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2008 | 455 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12420 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 225 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 432 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2021 | 16417 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 4690 | 0.060 |
Why?
|
| Pneumonia | 2 | 2020 | 325 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 465 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 509 | 0.050 |
Why?
|
| Adult | 6 | 2024 | 29734 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1706 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 120 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2022 | 28 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 740 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2803 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 33 | 0.050 |
Why?
|
| Phenotype | 2 | 2024 | 4273 | 0.040 |
Why?
|
| Public Health | 1 | 2022 | 267 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2020 | 49 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 651 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 104 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3174 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 776 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1617 | 0.040 |
Why?
|
| Lung | 1 | 2007 | 1496 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 715 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 208 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8249 | 0.040 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 80 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 11 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2021 | 546 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 50 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1420 | 0.030 |
Why?
|
| Nitrosation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 766 | 0.030 |
Why?
|
| Galectins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 61 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 702 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 110 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 908 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 23 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 124 | 0.030 |
Why?
|
| Chimerism | 1 | 2015 | 28 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 267 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1114 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 133 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 257 | 0.030 |
Why?
|
| Telomerase | 1 | 2015 | 168 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1121 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 233 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 207 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 193 | 0.030 |
Why?
|
| Papilloma | 1 | 2013 | 26 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 623 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 800 | 0.030 |
Why?
|
| Infliximab | 1 | 2013 | 65 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 277 | 0.030 |
Why?
|
| Urban Population | 1 | 1994 | 228 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 494 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2899 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 400 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1296 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 508 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2109 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1994 | 389 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 842 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1608 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 883 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2178 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2518 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 3080 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2831 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1157 | 0.020 |
Why?
|
| Morbidity | 1 | 2008 | 249 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Chorion | 1 | 2006 | 8 | 0.020 |
Why?
|
| Receptors, Angiotensin | 1 | 2007 | 21 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3095 | 0.020 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 22 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 34349 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 135 | 0.020 |
Why?
|
| Pregnancy | 2 | 2008 | 7223 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1994 | 3745 | 0.010 |
Why?
|
| Neutrophils | 1 | 2006 | 381 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 1168 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10340 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 3728 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 28 | 0.010 |
Why?
|
| Peru | 1 | 1994 | 47 | 0.010 |
Why?
|
| Bias | 1 | 1994 | 133 | 0.010 |
Why?
|
| Dyspnea | 1 | 1994 | 152 | 0.010 |
Why?
|
| Fever | 1 | 1994 | 299 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1994 | 2060 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1994 | 3312 | 0.000 |
Why?
|